ARCT Arcturus Therapeutics Holdings Forecast, Technical & Fundamental Analysis
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases... Show more
ARCT is expected to report earnings to rise 10.53% to -104 cents per share on August 10
Q2'26
Est.
$-1.05
Q1'26
Beat
by $0.17
Q4'25
Missed
by $5.31
Q3'25
Missed
by $6.02
Q2'25
Missed
by $3.55
The last earnings report on May 07 showed earnings per share of -94 cents, beating the estimate of -112 cents. With 336.84K shares outstanding, the current market capitalization sits at 193.70M.
A.I. Advisor
published General Information
General Information
a developer of technology and therapeutics for rare diseases
A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.
ARCT's RSI Indicator ascending out of oversold territory
The RSI Indicator for ARCT moved out of oversold territory on May 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In of the 28 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ARCT turned negative on June 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on May 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ARCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.074) is normal, around the industry mean (20.978). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ARCT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (4.730) is also within normal values, averaging (367.072).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
